Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs

NCT06641076 is registered in ClinicalTrials.gov with MoonLake Immunotherapeutics AG as lead sponsor.

NCT NCT06641076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06641076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs
Lead sponsor
MoonLake Immunotherapeutics AG
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 15, 2024
Completion date
February 4, 2027
Enrollment
960 (estimated)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic